Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer

被引:0
|
作者
Ishida, Y [1 ]
Kawakami, K [1 ]
Tanaka, Y [1 ]
Kanehira, E [1 ]
Omura, K [1 ]
Watanabe, G [1 ]
机构
[1] Kanazawa Univ, Sch Med, Dept Surg, Kanazawa, Ishikawa 9208641, Japan
关键词
TS polymorphism; 5-fluorouracil; gastric cancer; pharmacogenomics;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thymidylate synthase (TS) is a target enzyme of 5-fluorouracil (5-FU). TS has a polymorphic repeated sequence in the 5'-UTR and the polymorphism is associated with TS protein expression. TS polymorphism has been reported to link with the efficacy of 5-FU-based chemotherapy in colorectal cancer. In this study, we examined whether the association among TS polymorphism, TS mRNA expression and TS protein expression is also observed in gastric cancer tissues and whether the TS polymorphism is a prognostic factor for patients with gastric cancer. We quantified TS mRNA isolated from 115 gastric cancer tissues by real-time reverse transcription PCR and TS protein in 72 available samples by the fluoro-dUMP binding assay. These values were compared with TS genotypes of the samples determined by a PCR assay. The tumor with the 3R/3R genotype had higher TS protein expression than that with the 2R/3R genotype, although there is no association between the TS genotype and mRNA expression. The result suggests that mRNA translation is responsible for the genotype-dependent difference of TS protein expression, as is consistent with our previous observation in colorectal cancer. This association encouraged us to further examine the link of the TS genotype with the stage of disease and the Prognosis of the patients. The clinicopathological analysis showed that gastric cancers with the 3R/3R genotype are at a more advanced stage than those with the combined 2R/2R and 2R/3R genotype. We observed a longer survival in those patients with the combined 2R/2R and 2R/3R genotype, compared with the 3R/3R genotype, although it did not reach significance when the patients who had received the oral fluoropyrimidines therapy were analyzed. These results warrant further large-scale clinical study of the role of the TS genotyping for the prediction of efficacy using 5-FU-based chemotherapy and prognosis in gastric cancer.
引用
收藏
页码:2805 / 2809
页数:5
相关论文
共 50 条
  • [21] Association of 5-fluorouracil chemosensitivity with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in colorectal cancer
    Lee, S.
    Lee, W.
    Lim, S.
    Shin, J.
    Choi, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 92 - 92
  • [22] Thymidylate synthase gene polymorphisms is negatively associated with gastric cancer survival
    Chen, Jinfei
    Wang, Maggie Haitian
    Zee, Benny Chung-Ying
    CANCER RESEARCH, 2017, 77
  • [23] Expression of thymidylate synthase in relation to survival and chemosensitivity in gastric cancer patients
    Tsujitani, S
    Konishi, I
    Suzuki, K
    Oka, S
    Gomyo, Y
    Matsumoto, S
    Hirooka, Y
    Kaibara, N
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2000, 19 (02) : 189 - 195
  • [24] Gastric cancer with microsatellite instability displays increased thymidylate synthase expression
    Pereira, Marina A.
    Dias, Andre R.
    Ramos, Marcus F. K. P.
    Cardili, Leonardo
    Moraes, Rafael D. R.
    Zilberstein, Bruno
    Nahas, Sergio C.
    Mello, Evandro S.
    Ribeiro Jr, Ulysses
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 126 (01) : 116 - 124
  • [25] Thymidylate synthase expression in epithelial ovarian cancer: Relationship with thymidine phosphorylase expression and prognosis
    Fujiwaki, R
    Hata, K
    Nakayama, K
    Fukumoto, M
    Miyazaki, K
    ONCOLOGY, 2000, 59 (02) : 152 - 157
  • [26] Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer
    Marko Kornmann
    Karl H. Link
    Inga Galuba
    Kati Ott
    Wolfgang Schwabe
    Peter Häusler
    Peter Scholz
    Jörn Sträter
    Sucan Polat
    Bernhard Leibl
    Erika Kettner
    Christoph Schlichting
    Wolfram Baumann
    Harald Schramm
    Ute Hecker
    Karsten Ridwelski
    Jürgen H. Vogt
    Klaus-Ullrich Zerbian
    Frank Schütze
    Ernst D. Kreuser
    Detlev Behnke
    Hans G. Beger
    Journal of Gastrointestinal Surgery, 2002, 6 : 331 - 337
  • [27] Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer
    Kornmann, M
    Link, KH
    Galuba, I
    Ott, K
    Schwabe, W
    Häusler, P
    Scholz, P
    Sträter, J
    Polat, S
    Leibl, B
    Kettner, E
    Schlichting, C
    Baumann, W
    Schramm, H
    Hecker, U
    Ridwelski, W
    Vogt, JH
    Zerbian, KU
    Schütze, F
    Kreuser, ED
    Behnke, D
    Beger, HG
    JOURNAL OF GASTROINTESTINAL SURGERY, 2002, 6 (03) : 331 - 337
  • [28] Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer
    Park, DJ
    Stoehlmacher, J
    Zhang, W
    Tsao-Wei, D
    Groshen, S
    Lenz, HJ
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2002, 17 (01) : 46 - 49
  • [29] Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer
    David J. Park
    Jan Stoehlmacher
    Wu Zhang
    Denice Tsao-Wei
    Susan Groshen
    Heinz-Josef Lenz
    International Journal of Colorectal Disease, 2002, 17 : 46 - 49
  • [30] Thymidylate synthase gene polymorphism as a prognostic factor for the Korean patients with colorectal cancer
    Suh, KW
    Kim, JH
    Kim, YB
    Kim, J
    Jeong, S
    DISEASES OF THE COLON & RECTUM, 2004, 47 (06) : 1089 - 1089